Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Radioactive Drugs Research Comment Period Reopened By FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency will accept comments for 60 days on its regulation of radioactive drugs for certain research uses. The additional comment period will allow for feedback in the context of a draft guidance on exploratory INDs released in April, FDA says.

You may also be interested in...

Exploratory IND Guidance Emphasizes FDA Flexibility On Data Requirements

The agency believes that industry has not taken full advantage of the flexibility provided in investigational new drug regulations. The draft guidance advises sponsors on how to proceed with early Phase I, short-term "microdosing" studies.

FDA To Examine Radioactive Drugs Research Reg

The agency is holding a Nov. 16 public meeting to discuss whether new guidance on the use of radioactive drugs for research purposes should be developed, or if the current reg should be revised.

Merck Tax Settlement Could Be Smaller Than GSK’s $3.4 Bil. IRS Deal

A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts